Translations:Biosimilar/35/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
FuzzyBot (talk | contribs)
15,166 edits
Importing a new version from external source
 
(No difference)

Latest revision as of 09:54, 20 March 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (Biosimilar)
== Further reading ==
* {{cite journal | vauthors = Udpa N, Million RP | title = Monoclonal antibody biosimilars | journal = Nature Reviews. Drug Discovery | volume = 15 | issue = 1 | pages = 13–4 | date = January 2016 | pmid = 26678619 | doi = 10.1038/nrd.2015.12 | s2cid = 27954836 }}
* {{cite journal | vauthors = Jelkmann W | title = Biosimilar epoetins and other "follow-on" biologics: update on the European experiences | journal = American Journal of Hematology | volume = 85 | issue = 10 | pages = 771–80 | date = October 2010 | pmid = 20706990 | doi = 10.1002/ajh.21805 | s2cid = 205293428 | url = https://hal.archives-ouvertes.fr/hal-00552331/document | doi-access = free }}

Further reading

  • Udpa N, Million RP (January 2016). "Monoclonal antibody biosimilars". Nature Reviews. Drug Discovery. 15 (1): 13–4. doi:10.1038/nrd.2015.12. PMID 26678619. S2CID 27954836.
  • Jelkmann W (October 2010). "Biosimilar epoetins and other "follow-on" biologics: update on the European experiences". American Journal of Hematology. 85 (10): 771–80. doi:10.1002/ajh.21805. PMID 20706990. S2CID 205293428.
Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:Biosimilar/35/en&oldid=130344"